A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according ...

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...

For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. And ...

After learning of the warning letter, an investor accused Applied of knowing about these trial issues but not disclosing them ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed ...

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...